Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
13.90
0.00 (0.00%)
At close: Nov 17, 2026, 4:00 PM EST
13.89
-0.01 (-0.07%)
After-hours: Nov 17, 2026, 4:12 PM EST
Organon & Co. Revenue
Organon & Co. had revenue of $1.57B in the quarter ending September 30, 2026, a decrease of -1.75%. This brings the company's total for the last twelve months to $6.10B, down -3.21% year-over-year. In the year 2025, Organon & Co. had annual revenue of $6.22B, down -2.92%. That makes Organon & Co. the 2,283rd largest company in the world by revenue and 668th in the United States.
Revenue (ttm)
$6.10B
Revenue Growth
-3.21%
P/S Ratio
0.60
Revenue / Employee
$609,900
Employees
10,000
Market Cap
3.65B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Organon & Co. breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.22B | -187.00M | -2.92% |
| Dec 31, 2024 | 6.40B | 140.00M | 2.24% |
| Dec 31, 2023 | 6.26B | 89.00M | 1.44% |
| Dec 31, 2022 | 6.17B | -130.00M | -2.06% |
| Dec 31, 2021 | 6.30B | -228.00M | -3.49% |
| Dec 31, 2020 | 6.53B | -1.25B | -16.01% |
| Dec 31, 2019 | 7.78B | -2.00B | -20.46% |
| Dec 31, 2018 | 9.78B | -723.00M | -6.89% |
| Dec 31, 2017 | 10.50B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pfizer | 63.62B |
| AstraZeneca | 62.38B |
| Sanofi | 57.89B |
| Novo Nordisk | 50.70B |
| Bristol-Myers Squibb Company | 50.03B |
| GSK plc | 44.53B |
| Amgen | 38.90B |
| Gilead Sciences | 30.99B |
OGN News
- 5 days ago - Organon presents analysis of pooled post-hoc Phase 3 data on VTAMA cream - TheFly
- 5 days ago - Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI - Business Wire
- 9 days ago - Organon announces poster presentation on Hadlima at ACR Meeting - TheFly
- 12 days ago - Organon announces analysis of Phase 3 data of VTAMA cream - TheFly
- 12 days ago - Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting - Business Wire
- 18 days ago - Organon Announces Quarterly Dividend - Business Wire
- 18 days ago - Organon & Co. Quarterly report: Q3 2026 - Filings
- 4 weeks ago - Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing - Business Wire